Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sanoma Oyj
OMXH:SANOMA
|
FI |
Genfit SA
Accounts Receivables
Genfit SA
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Accounts Receivables
€40.3m
|
CAGR 3-Years
133%
|
CAGR 5-Years
120%
|
CAGR 10-Years
21%
|
|
|
Valneva SE
PAR:VLA
|
Accounts Receivables
€27.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Inventiva SA
PAR:IVA
|
Accounts Receivables
€10.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Accounts Receivables
€34m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
23%
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Accounts Receivables?
Accounts Receivables
40.3m
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's Accounts Receivables amounts to 40.3m EUR.
What is Genfit SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
21%
Over the last year, the Accounts Receivables growth was 433%. The average annual Accounts Receivables growth rates for Genfit SA have been 133% over the past three years , 120% over the past five years , and 21% over the past ten years .
